

Juraj Bodo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4783421/publications.pdf>

Version: 2024-02-01

19
papers

453
citations

1040056

9
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

747
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune Escape Mechanisms in Intravascular Large B-Cell Lymphoma: A Molecular Cytogenetic and Immunohistochemical Study. <i>American Journal of Clinical Pathology</i> , 2022, 157, 578-585.	0.7	5
2	Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 351-359.	2.5	5
3	Proteomic characterisations of ulcerative colitis endoscopic biopsies associate with clinically relevant histological measurements of disease severity. <i>Journal of Clinical Pathology</i> , 2022, 75, 636-642.	2.0	2
4	Decreased BIM expression in BCL2-negative follicular lymphoma: a potential mechanism for resistance to apoptosis. <i>Human Pathology</i> , 2021, 107, 1-8.	2.0	2
5	Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies. <i>Cell Death and Disease</i> , 2021, 12, 1061.	6.3	8
6	Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. <i>Cell Death and Disease</i> , 2020, 11, 941.	6.3	115
7	Inhibition of cyclin-dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma. <i>EJHaem</i> , 2020, 1, 161-169.	1.0	2
8	Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone, Lymphoplasmacytic, and Follicular Lymphomas. <i>American Journal of Clinical Pathology</i> , 2020, 153, 646-655.	0.7	9
9	Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. <i>Cancer Research</i> , 2020, 80, 2031-2044.	0.9	36
10	SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. <i>British Journal of Haematology</i> , 2019, 185, 145-147.	2.5	9
11	Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. <i>Cell Death and Disease</i> , 2019, 10, 924.	6.3	51
12	Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab. <i>Blood</i> , 2019, 134, 1515-1515.	1.4	0
13	Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations. <i>Blood</i> , 2019, 134, 1572-1572.	1.4	0
14	CAL2 Immunohistochemical Staining Accurately Identifies <i>CALR</i> Mutations in Myeloproliferative Neoplasms. <i>American Journal of Clinical Pathology</i> , 2016, 146, 431-438.	0.7	17
15	Acquired resistance to venetoclax (ABT-199) in <i>t(14;18)</i> positive lymphoma cells. <i>Oncotarget</i> , 2016, 7, 70000-70010.	1.8	59
16	CCMCL1: a new model of aggressive mantle cell lymphoma. <i>Blood</i> , 2015, 125, 2730-2732.	1.4	17
17	Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. <i>British Journal of Haematology</i> , 2015, 168, 765-768.	2.5	75
18	The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. <i>British Journal of Haematology</i> , 2013, 163, 72-80.	2.5	28

#	ARTICLE	IF	CITATIONS
19	HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 914-923.	4.9	13